ArticleJournal of bioenergetics and biomembranes2026
The fullerenol C
Article in Journal of bioenergetics and biomembranes, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fullerenols, which possess antioxidants, anti-inflammatory, and neuroprotective properties, can affect mitochondria. The effect of fullerenol C₆₀(OH)₃₆ on the structural-dynamic and functional parameters of mitochondria, both isolated in vitro and in vivo in Wistar rats, was studied. It was found that fullerenol at a dose of 10 mg/kg reduced bioenergetic parameters of both glutamate-dependent and succinate-dependent intracellular respiration in vivo. In the in vitro model system, fullerenol at a dose of 0.2 mg/ml significantly decreased the oxygen consumption rates in all metabolic states, leading to a reduction in the Lardy and Chance respiratory control ratios and the P/O ratio. Conversely, at a dose of 0.1 µg/ml, fullerenols significantly increased these respiratory parameters. Fullerenols, both in vivo and in vitro, increased the viscosity of annular and total mitochondrial membrane lipids. They did not affect the polarity of total lipids but decreased the polarity of annular lipids. Fullerenols at high doses induced significant conformational changes in membrane proteins, increasing their immersion into the lipid matrix. Our results demonstrate that fullerenols modulate mitochondrial bioenergetics and membrane structural dynamics in a dose-dependent manner, which may have implications for understanding both the cytoprotective and potentially cytotoxic effects of these nanoparticles.
Indexed as
Identifiers
42518000What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.